First Three Cancers Chosen for Cancer Genome Atlas Pilot

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 10
Volume 15
Issue 10

Brain, lung, and ovarian cancers have been chosen as the first cancers to be studied in the pilot phase of The Cancer Genome Atlas (TCGA) project

WASHINGTON—Brain, lung, and ovarian cancers have been chosen as the first cancers to be studied in the pilot phase of The Cancer Genome Atlas (TCGA) project, according to the National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI). These cancers, which collectively account for more than 210,000 US cancer cases each year, were selected because of the availability of biospecimen collections that met TCGA's requirements. TCGA was launched in December 2005 as a collaborative 3-year pilot project to test the feasibility of using large-scale genome analysis technologies to determine all of the important genomic changes involved in cancer.

The lung cancer biospecimens will come from CALGB's Lung Cancer Tissue Bank at Brigham and Women's Hospital, Boston. The source of the brain tumor (glioblastoma) specimens will be M.D. Anderson Cancer Center. The ovarian cancer biospecimens will be provided by the Gynecologic Oncology Group tissue bank at the Children's Hospital of Ohio State University, Columbus.

Recent Videos
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Related Content